ABSTRACT Chemical, pharmacokinetic, and pharmacodynamics 
EVOLUTION OF TEAM DEVELOPMENT OF PHARMACEUTICAL DATABASES AT WESLEY
In the mid-1990s, big pharma got involved with the management, searching, and integration of large molecular data files to discover, design, and optimize a diverse library of biology active compounds (Banville, 2006) . Such innovative and efficient Computer-Aided Drug Design (CADD) strategies exploit state-of-the-art computational technologies (in silico) to accelerate the drug development and structure optimization process (Mandal et al., 2009 ). Quantitative structure-activity relationships (QSAR) utilizing in silico tools are now typically employed to understand the relationships between biological activity and chemical drug structure (Ekins et al., 2007) .
To introduce core competencies and to increase awareness in biomedical, chemical, and health informatics, students at Wesley get exposed to such cutting-edge computing fields via interdisciplinary undergraduate research projects in chemistry, biology, electronic data-mining, computer programming, statistics, and medicine ( However, public usage of the information from our cancer drug database was heavily limited due to access of the underlying commercial platform. Hence, using the information from the KnowItAll ® Informatics System as a starting point, a relational cancer drug database (MySQL) was created as a result of a collaborative effort of researchers from Wesley College and Center for Bioinformatics & Computational Biology (CBCB) at the University of Delaware (D'Souza, AlAbed et al., 2011). One purpose of this expanded project is to further facilitate the analysis and/or the prediction of the chemotherapy compound's missing pharmacokinetic properties.
DESIGN OF A PUBLIC CANCER DRUG DATABASE AND THE PREDICTION OF AQUEOUS DRUG SOLUBILITY
In order to accomplish universal acceptance of a public cancer drug database, our goal was to design the database, load all existing compounds, and implement a web application that will allow users to view and edit the content of the database. The 85 FDA cancer drugs were initially chosen on the basis of the presence of at least one carbonyl containing functional group in the drugs chemical structure and on the availability of documented physicochemical parameters. We first designed a schema of the normalized relational database (D'Souza, AlAbed et al., 2011). The database design was aiming to achieve detailed information about each compound, their properties, as well as the methods that were used to collect those properties.
The information collected for each drug was first tabulated within a database created using the KnowItAll ® ADME/Tox Edition (Figure 1 ). This program gave an output of the drug that included the data about the different properties, such as the pH profile, and the source of the data itself. From that output, we collected our data and then began the process of editing the preexisting MySQL-database (D'Souza, AlAbed et al., 2011). We took the pH profiles for each drug and saved it into a separate file in order to add it to the database. When adding new data to this database, the schema for the database itself had to be modified (Figure 2 , changes are in bold).
Figure 2: E/R Diagram For The Cancer Drug Database
As a result of this work, a relational database has now been created (Figures 3-5) . The database interface allows the user to add new possible measurements of the compound properties coupled with the detailed description of the each method (Figure 3) , to browse among stored compounds and to visualize the structure (Figures 4, 5) , and to import new compounds and their corresponding structures (Figure 4 ).
The visualization of the compounds is accomplished by using Jmol, an interactive web browser applet. Jmol is a free, open source molecule viewer for students, educators, and researchers in chemistry and biochemistry. It is also a cross-platform, running on Windows, Mac OS X, and Linux/Unix systems. Hence, to aid in the use of determining missing clinical data, we have created a viable option that utilizes in-silico tools to predict missing pharmacokinetic parameters. This gives us the ability to enhance better drug delivery in the human body. In order to address pH-sensitive drug pharmacokinetics, we show (below) the predictive ability of our model using five examples of well-known cancer drugs that contain at least one carbonyl group in their chemical drug structure.
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Taxol
®
As an indicated first line or adjuvant chemotherapy for solid tumors like ovarian carcinoma, breast carcinoma or non-small cell lung carcinoma, Taxol ® (paclitaxel), intravenously administered, targets these tumors by its inherent very high bioavailability. Due to its low water solubility and high protein binding capacity, it directly redistributes from the intravascular compartment into peripheral compartment leading to high-targeted therapy on the intended solid tumor cancer cells. The solubility reported in experimental and in vitro models is mirrored in our in-silico predictions (illustrated in Figure 6 ), thus indicating the accuracy by which pharmacokinetic properties of such drugs can be predicted in anticipation of its utility. At the normal blood pH (7.4), Taxol ® is essentially not water soluble, a function that is predicted by our in-silico model using the functional groups' chemical characteristics of its parent compound. Extrapolating our model into its predictive utility, the selection of similar solid tumor effector chemotherapy agents can be more accurately achieved via narrowing on the specific pharmacokinetic parameters -in this case, water solubility -thus cutting considerably on the cost and time needed to bring similar drugs into clinical utility. Hematopoietic malignancies, in their advanced stages, tend to involve other solid organs outside the lymph nodes and marrow spaces. As such, they need to be targeted in the intravascular and extravascular compartment including across the blood brain barrier. Chemotherapeutic agents that are used in these settings, such as Matulane ® for advanced stage Hodgkin's Lymphoma, are chosen for their specific pharmacokinetic parameters, notably their aqueous solubility. Due to its good solubility at gastric pH as well as at plasma pH, Matulane ® is the perfect candidate. It is can be readily absorbed when given orally, thus there is an ease of administration. Completely soluble in blood, cross the blood brain barrier, it thus has the ability to be readily bioavailable in all potential compartments. The kidneys, decreasing the amount of potential toxicities, also can readily eliminate it. All these characteristics are mainly due to its water solubility. The accuracy by which our computer model was able to predict its solubility is documented in Figure 7 . Mirroring the utility and applicability of our findings on formulating similar drugs, agents with similar solubility can be predicted with measurable accuracy using our model. Thus, in filtering through potential chemotherapeutic candidates with proven in-vitro clinical efficacy, our model can help in narrowing down the search. In formulating drugs that are intended for treatment of solid tumor with the primary metabolite or molecule being insoluble in aqueous solutions, a parenteral rout of administration is not very practical. The drug has to be administered in a continuous mode to achieve comparable results to its in vitro action, and a functional group needs to be added to make the whole compound water soluble. An example is Nexavar ® , a chemotherapeutic agent used primarily to treat renal cell carcinoma and unresectable hepatocellular carcinoma. The active ingredient, sorafenib tosylate is a kinase that achieves its steady state blood level after seven days of continuous oral administration of 400 mg twice daily. This needs to be maintained for a total of 28 days to produce its optimum inhibitory effect on tumor growth. Thus the best way to achieve this is through the oral route -a potential problem with an insoluble molecule like sorafenib -a parameter that we were able to predict with high comparable accuracy using our computer model. We were also able to predict the solubility at gastric pH and plasma pH after pairing the active ingredient with the functional group (Figure 8 ). It also follows that the applicability of our model is of practical utility in formulating similar drugs with specific clinical/pharmacokinetic parameters. While the above mentioned kinase is insoluble at acidic, as well as basic pH, and can only be clinically useful if a functional group is added, other kinase inhibitors, such as Gleevec ® (Imatinib), lends itself perfectly due to its excellent solubility at low pH and very low solubility at neutral pH. Gleevec ® is very effective in treating Philadelphia chromosome positive hematologic malignancies such as CML and ALL. It can also be used in other sarcomas such as GIST. Being very soluble at low pH, it can be given orally with excellent absorption, yet with its insolubility at blood pH, it can attain therapeutic levels fast, get slowly eliminated and have a high volume of distribution. As illustrated below (Figure 9 ), our model accurately predicts this biphasic solubility as a function of the pH. This also lends itself easily to pre-experimental phases in selecting drugs that are intended to be similarly administered with a comparable eventual volume of distribution. Perhaps the best practical application for our model is in formulating targeted therapy whereby effector agents are known for their in-vitro action, yet their solubility prohibits effective delivery to the target organs/tumors. Having the ability to accurately predict the behavior of the major molecule/metabolite at different pH levels make it possible to manipulate the drugs in its pre-experimental form, thus giving us an edge in predicting the final product behavior at the given pH. This concept is best-illustrated by applying our computer model to a drug like Doxil The Bio-Rad KnowItAll ® website: http://www. 
